Experimental autoimmune encephalomyelitis (EAE) is a T-cell-mediated autoimmune disease. Chemokine receptor CCR5 has been shown to be essential for the T-cell recruitment to the inflammatory site in EAE. In this study, we assumed that an immunotoxin directed at CCR5 + cells would be able to reduce the disease activity of EAE. A recombinant immunotoxin, DT390-RANTES-SRa, was constructed in an eukaryotic cell expression plasmid consisting of regulated on activation normal T cells expressed and secreted (RANTES) as the targeting moiety and DT390 as the toxic moiety. DT390-RANTES was expressed in vitro and was highly toxic to activated mouse T cells with the inhibitory concentration 50 at 0.18 ng/ml. To evaluate whether DT390-RANTES was effective in preventing EAE, C57BL/6 mice were immunized with myelin basic protein, emulsified with complete Freund's adjuvant and were treated by injecting cationic liposome-embedded plasmid DNA into the muscle of hind limbs. Mice treated with DT390-RANTES-SRa developed a much milder EAE compared to mice treated with phosphate-buffered saline or the empty plasmid DNA. Much less CCR5 + -infiltrating cells were found in the central nervous system in DT390-RANTES-SRa-treated mice than in the control mice. This study indicates that recombinant immunotoxin can be expressed in vivo, and targeting CCR5 can attenuate the disease activity of EAE in mice.
Introduction
Experimental autoimmune encephalomyelitis (EAE) is a T-cell-mediated autoimmune disease. EAE has similar clinical symptoms, pathological changes in central nervous system (CNS) and biochemical index to multiple sclerosis. 1, 2 In EAE, T cells are activated by autoantigen immunization, 3, 4 and these activated T cells migrate to the CNS and induce inflammatory reaction. The migration of the activated T cells depends on the surface expression of chemokine receptors. Among these receptors, CCR5 has been shown to be essential for the T-cell recruitment to the inflammatory site in EAE. 5, 6 Therefore, CCR5 can be used as a specific surface marker to identify the effector T cells as well as a target for deletion of these effector cells for treating EAE. 7, 8 Immunotoxin is a hybrid molecule that consists of a targeting moiety and a toxic moiety. [9] [10] [11] [12] Truncated diphtheria toxin (DT) is often used as a toxic moiety because it is highly toxic to eukaryotic cells. Monoclonal antibodies as well as cytokines and chemokines are used as targeting moiety in the construction of recombinant immunotoxins because of their specificity and highbinding affinity to the target cells. In this study, we assumed that an immunotoxin directed at CCR5 + cells would be able to reduce the disease activity of EAE. Gene therapy as a delivery tool has been used repeatedly and proven to be effective in animal EAE treatment. [13] [14] [15] Therefore, we also hypothesized that a recombinant immunotoxin could be expressed in vivo and achieve the therapeutic efficacy. Based on these assumptions, we constructed a recombinant immunotoxin in an eukaryotic cell expression plasmid consisting of regulated on activation normal T cells expressed and secreted (RANTES) as the targeting moiety and DT390 as the toxic moiety in the hope that it could be expressed in vivo and useful in the treatment of EAE.
Results

Expression of DT390-RANTES-SRa in eukaryotic cells
The eukaryotic cell expression plasmid DT390-RANTESSRa ( Figure 1 ) was transfected to NIH3T3 cells. The expression of DT390-RANTES was detected by indirect immunofluorescence using antibodies directed at RANTES and DT separately. NIH3T3 cells that were transfected with DT390-RANTES-SRa plasmid appeared to be positive compared to the untransfected cells, cells transfected with the empty plasmid and a normal goat serum as control ( Figure 2 ). The culture supernatant of the cells with DT390-RANTES-SRa transfection was examined with enzyme-linked immunosorbent assay (ELISA) to quantify the RANTES concentration, it was shown to be around 2 ng/ml (data not shown), sufficient for in vitro toxicity assay.
Cytotoxic assay of the recombinant immunotoxin DT390-RANTES
The culture supernatants of cells transfected with DT390-RANTES-SRa were harvested and used for protein synthesis inhibition assay on T cells activated by ConA. The Result is shown in Figure 3 . DT390-RANTES appeared to be highly toxic to the activated mouse T cells, with the inhibitory concentration 50 at 0.18 ng/ml.
Treatment with DT390-RANTES-SRa attenuates EAE
Based on the in vitro experimental results, we learned that DT390-RANTES could be effectively expressed by eukaryotic cells and the expressed product was highly toxic to the activated T cells. Therefore, DT390-RANTESSRa plasmid was used to prevent murine EAE by injecting into the muscle of the hind limbs. As shown in Figure 4 , the expression of the recombinant DT390-RANTES was detected by probing with both anti-RANTES and anti-DT antibodies. The recombinant protein was detected as early as 4 h (data not shown) after the injection of the plasmid DNA into the muscle, and could be detected 72 h after the transfer.
Six days after the first immunization with myelin basic protein (MBP), in mice treated with phosphate-buffered saline (PBS) or the empty plasmid EAE symptoms started to appear, including laggard behavior, atony of tails and abduction of hind-limbs; between day 15 and 20, more severe symptoms of EAE occurred to these mice, including decrease of avoirdupois, paralysis of hind-limbs and moribund. Severity of EAE symptoms began to reduce from 21 days after the immunization and disappeared by day 35. In contrast, mice treated with DT390-RANTES-SRa plasmid developed EAE later, starting averagely on day 14 (vs PBS or empty plasmid-treated mice on day 6). The mean duration of EAE in these mice was 20 days (vs 30 days of PBS or empty plasmid-treated mice). Furthermore, as presented in Figure 5 , the peak clinical scores of EAE in DT390-RANTES-SRa plasmid-treated mice were averagely 1.1770.29, much less (Po0.05) than that of the PBStreated mice (2.1770.17) and empty plasmid-treated mice (2.1070.29).
DT390-RANTES-SRa therapy reduced CCR5
+ -infiltrating cells in CNS DT390-RANTES-SRa therapy could alleviate the symptoms of EAE. The mechanism could be that DT390-RANTES killed the activated T cells that expressed CCR5. Using an anti-mouse CCR5 monoclonal antibody, the expression of CCR5 in infiltrating inflammatory cells in the CNS was determined. Numerous CCR5 + cells in the white matter, pia matter, gray matter, especially the perivascular areas, were observed in mice treated with PBS and the empty plasmid in specimens obtained 20 days after the first immunization. Nevertheless, CCR5 + cells infiltrating in the CNS tissue samples harvested in the same time range were much less in the DT390-RANTES-SRa-treated mice ( Figure 6 ). In samples taken on day 25, the time that EAE symptoms reached the peak in DT390-RANTES-SRa plasmid-treated mice, CCR5 + cells were still much less in DT390-RANTES-SRa plasmid-treated mice than in mice treated with PBS or the empty plasmid (data not shown). The normal control had no CCR5 + cells in the CNS.
DT390-RANTES-SRa therapy affects T-helper cells in vivo
Serum samples were collected from the mice every 3 days for detecting interferon-g (IFN-g) and interleukin-4 (IL-4). IFN-g level, 45.4772.35 pg/ml, in DT390-RANTES-SRa plasmid-treated mice was significantly lower (Po0.05) than that in mice treated with PBS (337.70733.57 pg/ml) or mice treated with the empty plasmid (320.15726.13 pg/ml). The value of IFN-g in DT390-RANTES-SRa-treated mice peaked about 10 days later than in the mice treated PBS or empty plasmid ( Figure 7a ). The IL-4 serum level reached a peak at 58.8672.01 pg/ml in DT390-RANTES-SRa-treated mice, compared to 45.3674.84 pg/ml in PBS-treated mice and 33.7873.05 pg/ml in empty plasmid-treated mice (P40.05; Figure 
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Discussion EAE in the mouse is induced by autoimmune T cells. The T-cell migration from lymphoid tissue to the CNS is essential for the initiation of the disease. T-cell migration into the inflammatory sites relies on the chemokine and chemokine receptor interaction. In this study, we used chemokine receptor CCR5 as the target for depletion of the activated autoimmune T cells in the hope to prevent EAE. This rationale was based on previous studies showing that infiltrating inflammatory T cells in the CNS of EAE-suffering animals expressed CCR5. 16 This CCR5 expression was also confirmed in the present study. In the control mice that were treated with PBS or the control plasmid DNA, numerous CCR5 + cells were observed in the CNS lesions.
The depletion of the CCR5 + cells was achieved by a RANTES-directed DT390-based recombinant immunotoxin. RANTES specifically binds to CCR5 on the cell surface, [17] [18] [19] and upon binding, the ligand receptor complex will be endocytosed into the cell interior. This endocytosis process will transport the DT390 toxin moiety into the cell and there it inhibits the protein synthesis that eventually kills the cell. Traditionally, recombinant immunotoxin is expressed in vitro by bacteria or yeast. 9, 20, 21 The protein product is concentrated and purified for clinical and experimental use. Although this pathway can guarantee the precise delivery dosage, it is complicated and the plasma level of the recombinant immunotoxin could vary tremendously owing to fast clearance of the recombinant protein in vivo. 22, 23 In this study, we adopted a novel therapeutic mode. We injected plasmid DNA encoding DT390-RANTES into the mouse muscle, and therefore the expression of the recombinant protein was achieved in the mouse. This therapy was proven to be effective. Figure 5 DT390-RANTES attenuates the murine EAE activity. EAE was induced and the plasmid treatment was conducted on the first day and the third day after the first MBP immunization. EAE activity was scored in the mice as reported previously. Each group consisted of 10 mice.
In mice that were treated with the recombinant DT390-RANTES-encoding plasmid DNA, EAE onset was delayed and the clinical scores were significantly lower than the control mice. Furthermore, in CNS much less infiltrating inflammatory cells expressing CCR5 were found in the treated mice than in the control mice. The efficacy of the in vivo therapy of the recombinant immunotoxin was also revealed by the reduced IFN-gexpressing T cells and the plasma level of IFN-g in the treated mice. Targeting CCR5 can be achieved by other approaches, such as small molecule drugs to block the signaling pathway, [24] [25] [26] or antibodies to block the binding of the ligands to CCR5. 27 The result is to disable the chemokine signaling and the T-cell migration. The current study presents a method that selectively depletes the receptorexpressing cells physically. Therefore, it can be used in combination with small molecules in order to enhance the therapeutic efficacy as they have two different action mechanisms.
CCR5 is preferentially expressed by activated T cells, 28 but this does not exclude the possibility of other cells in the body to express this receptor. In the latter case, the recombinant imunotoxin DT390-RANTES will kill these cells as well, and consequently cause side effects.
Although we were unable to find any obvious side effects in our mouse model with the gene therapy, severe side effects could occur in the humans if similar therapy is used in the clinic considering the difference between rodents and the humans. To prevent the progress of severe side effects, using inducible expression vector will be a better option. In summary, we have constructed a recombinant immunotoxin DT390-RANTES, and used the eukaryotic cell expression plasmid DNA to treat mice with EAE. This therapy delayed the onset of EAE and also reduced the disease activity. This novel therapeutic approach may prove to be useful clinically in the future.
Materials and methods
Preparation of antigen
MBP was extracted from fresh spinal cord of the ox using the Kies method. 29 Complete Freund's adjuvant was purchased from Sigma (St Louis, MO, USA). Heat-killed Bordetella pertussis vaccine (3-9 Â 10 12 cell/ml) was provided by Biological Research Institution of Chengdu (Chengdu, Sichuan, China). 
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Mice Female C57BL/6 mice (6-8 weeks old) were obtained from the animals breeding facility of Sichuan University (Chengdu, Sichuan, China) and maintained under pathogen-free condition in the animal facility. All experiments were carried out with the institutional approval.
Eukaryotic expression plasmid construction
The eukaryotic expression plasmid SRa including DT390 fragment was a kind gift from Dr David M Neville (NIMH, National Institutes of Health, Bethesda, MD, USA). Murine RANTES cDNA was reversely transcribed from RNA isolated from the liver of C57BL/6 female mouse using a kit purchased from TaKaRa Biotechnology Company (Dalian, Liaoning, China). The primer sequences of RANTES were 5 0 -CAT GCC ATG GGC CTC ACC ATA TGG CTC GGA C-3 0 and 5 0 -CCG GAA TTC CTA GCT CAT CTC CAA ATA GTT-3 0 . The restriction endonuclease NcoI (underline) and EcoRI (underline) sites and protecting bases were added, respectively, on the two sides of the RANTES primers for cloning. Polymerase chain reaction products were confirmed by gelose gel electrophoresis and DNA sequence. The RANTES fragment was then cloned into SRa plasmid following the DT390 fragment after restriction endonuclease NcoI and EcoRI digestion to generate a novel recombinant plasmid DT390-RANTES-SRa (Figure 1 ). DT390-RANTES-SRa was transfected to Escherichia coli JM109 and extracted in large scale using the Endofree Plasmid Maxi Kit (Qiagen, Hilden, Germany).
Cell transfection and in vitro proliferation assay
The purified eukaryotic expression plasmid DT390-RANTES-SRa was transfected into NIH3T3 cells by Polyfect Transfection Reagent (Qiagen, Hilden, Germany). The expression of DT390-RANTES protein inside the cells was detected by immunofluorescence assay using antibodies directed at DT and RANTES purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA, USA). The spleens of C57BL/6 mice were obtained and single spleen cell suspension was prepared in RPMI 1640. Then, MNCs were obtained by density gradient centrifugation on NycoPrep 1.077A (Axis-shield, Oslo, Norway), and the cell density was adjusted to 5 Â 10 6 cells/ml. Cells were stimulated by concanavalin A (ConA, 5 mg/ml; Sigma) in RPMI 1640 supplemented with 10% fetal calf serum (FCS) for 72 h at 371C in humidified atmosphere containing 5% CO 2 . Activated mouse T cells were then used as target cells for toxicity assay of DT390-RANTES. Protein synthesis inhibition assay was performed as described. 30 The immunotoxin was incubated with the target cells (5 Â 10 4 cells/well in a 96-well plate) for 20 h. A 1-h pulse of [ 3 H]leucine (4.5 mCi/ml) was given before cells were collected onto filters with a Skatron harvester. Samples were counted in a Beckman scintillation counter. Each experiment was performed in four replicates. Results were calculated into a mean value7s.d.
EAE induction and therapy
The recombinant plasmid DT390-RANTES-SRa and the empty plasmid SRa were embedded with cationic liposome as reported previously. 31 EAE was induced in mice by intradermal injection of 100 ml MBP (1.5 mg/ml) emulsified with 100 ml complete Freund's adjuvant and 100 ml heat-killed B. pertussis vaccine (0.6-1.8 Â 10 6 cells). A second injection of the same formulated reagents was given 7 days after the initial immunization. Thirty C57BL/6 female mice were induced to develop EAE. Among these mice, 10 were treated with DT390-RANTES-SRa, 10 were treated with PBS and 10 were treated with empty SRa plasmid. Besides, 10 untreated normal C57BL/6 female mice were used as negative controls. The plasmid treatment was conducted on the first day and the third day after the first MBP immunization. Cationic liposome-embedded plasmid DNA (50 mg) in 50 ml PBS (0.01 M (pH 7.4)) were injected intramuscularly. 32 PBS injection was given for the PBStreated mice. EAE was evaluated daily using the following clinical scores: 33 0, clinically normal; 1, limp tail; 2, partial hind leg paralysis; 3, total hind leg or partial hind and front leg paralysis; 4, total hind leg and partial front leg paralysis; and 5, moribund or dead.
Expression of DT390-RANTES in the muscle
The inoculated muscle tissues were excised from the killed mice at 4, 8, 12, 24, 36 and 72 h after the plasmid transduction, and then fixed in formalin overnight. Formalin-fixed muscle samples were embedded in paraffin and cut into 5-mm sections. These sections were deparaffinized in xylol and re-hydrated through a series of ethanol and PBS, and then incubated in 0.6% H 2 O 2 for 30 min at room temperature (RT) to block endogenous peroxidase. Sections were then incubated in 1% goat serum in PBS for 1 h. The primary antibody used was goat polyclonal anti-mouse RANTES (1:200 dilution) or anti-DT (1:200 dilution). After washing, a biotin-labeled rabbit anti-goat antibody (Boster Biotechnological Corp., Wuhan, Hubei, China) was applied. Following 
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Immunohistochemistry to detect CCR5 + cells
The mice were affused through left ventricles using PBS containing 4% paraformaldehyde and PBS, respectively, under general anesthesia. Cerebrum, cerebellum and spinal cord were obtained, and then immersed into PBS containing 4% paraformaldehyde for 24 h and in 20% saccharose dehydrated for another 24 h. 34, 35 The tissues were cut into 5-mm-thick serial sections. Sections were incubated with a goat anti-mouse CCR5 antibody (Boster Biotechnological Corp., Wuhan, Hubei, China) at 41C overnight. After washing, a rabbit anti-goat secondary antibody labeled with horseradish peroxidase (Boster Biotechnological Corp.) was applied, and then incubated at RT for 4 h. DAB was used for color development.
The enzyme-linked immunosorbent assay
Blood samples were collected from the retro-orbital plexus of the mice. Serum levels of IFN-g and IL-4 were determined by using ELISA kits purchased from R&D Systems (Minneapolis, MN, USA). Experimental procedures proposed by the manufacturer were followed.
Flow cytometry
Mouse spleen cells were obtained as described previously. After washing and re-suspending in RPMI-1640 Prevention of murine EAE by DT390-RANTES Y Jia et al supplemented with 10% (v/v) FCS, MNCs were cultured in the six-well plate in the presence of 100 ng/ml of phorbol-12-myristate-13-acetate (Sigma, St Louis, MO, USA), 3 mM of monensin (Sigma) and 1 mg/ml of ionomycin (Sigma) overnight at 371C in humidified atmosphere containing 5% CO 2 . 36, 37 After culture, cells were used for flow cytometric analysis. Fluorescein isothiocyanate (FITC)-labeled anti-mouse CD3 and phycoerythrin (PE)-labeled anti-mouse CD19 (BD Pharmingen, San Diego, CA, USA) antibodies were added to the cells and incubated in the dark at RT for 20 min. After washing, cells were re-suspended and fixed with 2% paraformaldehyde. Cells were then re-susupended in 500 ml PBS after removal of the fixation fluid by centrifuge before the analysis using a Beckman-Coulter Epics Elite ESP Flow Cytometer (Beckman Coulter Corp., Miami, FL, USA). For intracellular cytokine staining, FITC-labeled anti-mouse CD3 antibody and PE-Cy5-labeled anti-mouse CD8 antibody (BD Pharmingen) were added to the cells and incubated in the dark at RT for 20 min. After washing, cells were re-suspended and fixed with 2% paraformaldehyde. Then, cells were permeabilized with 0.5% saponin at RT for 15 min after removal of the fixation fluid by centrifuge. PE-labeled anti-mouse IFN-g antibody (BD Pharmingen), PE-labeled anti-mouse IL-4 antibody (BD Pharmingen) or an isotype control antibody (BD Pharmingen) were added separately to the cells and incubated at 41C RT in the dark for 30 min. After washing, cells were resusupended in 500 ml of PBS before the analysis using a Beckman-Coulter Epics Elite ESP Flow Cytometer (Beckman Coulter Corp.). Data analysis was carried out using the Becton Dickinson Cell Quest 3.1 software.
Statistical analysis
The mean clinical scores7s.d. and the cytokine levels of peripheral blood7s.d. were analyzed by the KruskalWallis test, if Po0.05, the differences between each two groups were analyzed by the Mann-Whitney U-test. The mean percentages of T and B cells were analyzed by the one-way analysis of variance test. A value of Po0.05 was considered significant.
